Skip to Main Content

Phase 2a Evaluation of Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Patients With Primary Sclerosing Cholangitis (PSC)

Conditions

Diseases of the Digestive System - Liver

Phase IIA

What is the purpose of this trial?

The main purpose of this study is to determine the safety and tolerability of PLN-74809 compared to a placebo, when taken daily for up to 12 weeks. The study also aims to determine how the body processes the study medication and assess any changes in the condition PSC.

If you have been diagnosed with primary sclerosing cholangitis (PSC), a rare, long-term liver disease affecting the bile ducts inside and outside the liver you could be eligible to participate in a research study by Pliant Therapeutics, investigating a medication named PLN-74809 for the treatment of PSC.

  • Trial with
    Pliant Therapeutics Inc.
  • Start Date
    09/22/2021
  • End Date
    02/28/2022

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    12/17/2021
  • Study HIC
    #2000029307